First Successful Phase III mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%

Moderna's personalized mRNA cancer vaccine has become the first to succeed in a Phase III trial, cutting melanoma recurrence risk by 42%. The milestone is seen as a breakthrough for both cancer vaccines and AI-assisted drug development.

2026-10-25 ~ 2026-10-25 · 2 related posts

• Moderna's phase 3 cancer vaccine cuts tumor recurrence by 42% — mariolefebvre · 2026-10-25
• First successful phase 3 trial: bespoke mRNA vaccine cuts melanoma recurrence risk — Competitive_Travel16 · 2026-10-25